Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LTR PharmaASX:LTP -2.08%13 3-Year Book Growth Rate is 137.40% as of Dec. 2025, which is at its 10-year median of 137.40. GuruFocus rates ASX:LTP with a GF Score™ of 13/100. Among 1,131 Biotechnology companies, LTR Pharma ranks better than 99.12% on this metric.
During the past 12 months, LTR Pharma's average Book Value per Share Growth Rate was -22.10% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 137.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 5 years, the highest 3-Year average Book Value per Share Growth Rate of LTR Pharma was 137.40% per year. The lowest was 137.40% per year. And the median was 137.40% per year.
LTR Pharma (ASX:LTP) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
LTR Pharma 3-Year Book Growth Rate Related Terms
ASX:LTP vs VRTX, REGN, RVMD: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, LTR Pharma's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LTR Pharma 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LTR Pharma's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where LTR Pharma's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 137.40% mean?
LTR Pharma (ASX:LTP) has a 3-Year Book Growth Rate of 137.40% as of Dec. 2025. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for LTR Pharma and its competitors. This is near median its historical median of 137.40. Over the past decade, LTR Pharma's 3-Year Book Growth Rate has ranged from 137.40 to 137.40. According to the industry distribution chart, LTR Pharma ranks #10 out of 1131 companies in the Biotechnology industry, placing it in the top 0.90000000000001%.
Is LTR Pharma's 3-Year Book Growth Rate too high?
LTR Pharma's current 3-Year Book Growth Rate of 137.40% is near median its 10-year median of 137.40. Over the past 10 years, this metric has ranged from a low of 137.40 to a high of 137.40. Based on the distribution chart, LTR Pharma ranks #10 out of 1131 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, LTR Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's 3-Year Book Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, LTR Pharma ranks #10 out of 1131 companies for 3-Year Book Growth Rate. This places LTR Pharma in the top 1% of its industry — outperforming the majority of peers. Historically, LTR Pharma's own 3-Year Book Growth Rate has ranged from 137.40 to 137.40 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for LTR Pharma and its competitors. LTR Pharma's current 3-Year Book Growth Rate is 137.40%, which is near median its own 10-year median of 137.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current 3-Year Book Growth Rate of 137.40%. The current 3-Year Book Growth Rate is 137.40%, which is near median its 10-year median of 137.40. LTR Pharma's overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current 3-Year Book Growth Rate is 137.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
13GF Score
Get the complete analysis for ASX:LTP
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LTP has been successfully added to your 
